Pharmaceutical companies are responsible for the ideation, development, and marketing of new drugs and therapies.  Data is critical to pharmaceutical companies to pursue innovative R&D and commercial strategies; however, given the sensitivity of these datasets, third-party data access concerns, internal security and governance requirements, and cross-border regulations limit pharmaceutical companies from being able to fully implement their data strategy.

Current approaches to address this problem are limited — anonymization and data governance technologies reduce data quality and further reinforce information silos.  Today, researchers and data scientists may wait weeks or even months for access to even internal datasets, and third-party data sources, such as data from hospital systems, can take years to integrate, if it can be done at all.  Worse still is that current methods to protect data do not provide any meaningful privacy assurances; anonymized data is easily reverse engineered, creating substantial regulatory and reputational risk.

Pharmaceutical companies need a new mechanism for safely democratizing data across internal silos and acquiring third-party data sources while protecting sensitive information about individuals.

This E-Book Covers

  • A review of the challenges faced by pharmaceutical companies to access
    and share data
  • A technology overview of privacy-preserving analytics, and how they apply to the pharmaceutical industry
  • Use cases for pharmaceutical company leaders

Please enter your details, and the E-Book will be sent to your email.

This website stores cookies on your computer to improve your website experience and provide more customized services to you. Read the cookie policy here.

I accept